Artelo Biosciences

Artelo Biosciences

Yahoo Finance • 17 days ago

Artelo Biosciences Enrolls First Patient In Phase 2 Glaucoma Study Of ART27.13

(RTTNews) - Artelo Biosciences, Inc. (ARTL), a clinical-stage pharmaceutical company focused on lipid-signaling pathways, announced the enrollment of the first patient in the Phase 2 DREAM study evaluating ART27.13 in patients with glaucom... Full story

Yahoo Finance • 17 days ago

Artelo Enrolls First Patient In Phase 2 DREAM Trial For ART27.13 In Treating Intralocular Pressure

(RTTNews) - Artelo Biosciences Inc. (ARTL), a clinical-stage pharmaceutical company, on Monday announced the enrollment of the first patient in the Phase 2 DREAM trial for ART27.13 in treating glaucoma or ocular hypertension. Glaucoma aff... Full story

Yahoo Finance • last month

Artelo Biosciences Announces Results from a Nonclinical Osteoarthritis Study Supporting ART26.12 as a Potential First-in-Class New Therapy for Chronic Pain Conditions

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments fo... Full story

Yahoo Finance • 3 months ago

Pre Market Movers: GNTA, HCWC, ZCMD Set The Path

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premark... Full story

Yahoo Finance • 4 months ago

Artelo Announces Peer-Reviewed Publication Supporting its FABP5 Inhibitor ART26.12 as a Novel Pain Treatment with a Potentially First-in-Class Profile

Demonstrates ART26.12’s Differentiated Profile as a Promising Pain Treatment Ahead of Planned Multiple Ascending Dose Study This Year Phase 1 SAD Study Exhibited Excellent Safety with Zero Adverse Events Attributed to ART26.12 SOLANA BEA... Full story

Yahoo Finance • 5 months ago

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SOLANA BEACH, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) today announced the closing of its previously announced private placement of 3,188,407 shares of common stock (or pre-funded warrant in lieu... Full story

Yahoo Finance • 5 months ago

Artelo Biosciences Expansion into $16.3B Glaucoma Market, Via Fully Funded Study, Highlights Multi-Platform Pipeline Strength

BRISTOL, Tenn., March 25, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL) is drawing increased attention following its expansion into the $16.3 billion glaucoma market through a fully funded investigator-sponsored clinic... Full story

Yahoo Finance • 5 months ago

Biotech Breakthroughs and Strategic Pivots Fuel Market Momentum

DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- Today’s action highlights biotech and healthcare innovators advancing novel therapies and strategic platforms amid rising demand for targeted treatments and efficient global access. With the bio... Full story

Yahoo Finance • 5 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Li Bang International Corporat 715,505,563 0.11 0.0716 0.0779 +0.0472 YY... Full story

Yahoo Finance • 6 months ago

Artelo Biosciences announces 3-for-1 reverse stock split

Artelo Biosciences (ARTL) announced that on February 27, 2026, Artelo’s Board of Directors approved a 3-for-1 reverse stock split of the Company’s common stock. The Company’s common shares will begin trading on a split-adjusted basis on th... Full story

Yahoo Finance • 6 months ago

Artelo Biosciences Announces Reverse Stock Split

SOLANA BEACH, Calif., March 06, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments fo... Full story

Yahoo Finance • 9 months ago

Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models

SOLANA BEACH, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for... Full story

Yahoo Finance • 9 months ago

Artelo Biosciences GAAP EPS of $3.97

* Artelo Biosciences press release [https://seekingalpha.com/pr/20303587-artelo-biosciences-provides-business-update-and-reports-third-quarter-2025-financial-results] (ARTL [https://seekingalpha.com/symbol/ARTL]): Q3 GAAP EPS of $3.97.... Full story

Yahoo Finance • 10 months ago

Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit

ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and Activity Improvements in... Full story

Yahoo Finance • 11 months ago

Artelo Biosciences Announces Closing of $2.0 Million Public Offering

SOLANA BEACH, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 11 months ago

Artelo Biosciences launches underwritten public offering to raise capital

Artelo Biosciences (NASDAQ:ARTL [https://seekingalpha.com/symbol/ARTL]) has commenced an underwritten public offering [https://seekingalpha.com/pr/20248127-artelo-biosciences-announces-proposed-underwritten-public-offering] of its common s... Full story

Yahoo Finance • 11 months ago

Artelo Biosciences Announces Proposed Underwritten Public Offering

SOLANA BEACH, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 12 months ago

Artelo Biosciences Announces Publication of Preclinical Data Demonstrating Superior Efficacy and Bioavailability of ART12.11 in Reducing Stress-Induced Depression and Anxiety Symptoms

SOLANA BEACH, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 12 months ago

Artelo Biosciences Announces Closing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer,... Full story

Yahoo Finance • 12 months ago

Let's take a look at the stocks that are in motion in today's session.

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] TOP GAINERS TICKER CHANGE COMMENT CIGL [https://www.chartmill.com/stock/quote/CIGL/profile] 91.84% CON... Full story